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دور تركيبة خليط الكالسيبوتريول والبيتاميثازون ديربوبيونات اهلالمية يف عالج 
اإللتهابات اجللدية املتوسطة إىل الشديدة يف فروة الرأس
فيليك�س بون-بن ياب
abstract: Objectives: This study aimed to investigate the off-label use of a combination calcipotriol plus 
betamethasone dipropionate (CBD) gel in the treatment of moderate-to-severe scalp seborrhoeic dermatitis 
(SSD). Methods: This retrospective study involved 32 patients with SSD who were prescribed CBD gel at the 
Subang Jaya Medical Centre, Selangor, Malaysia, between January 2016 and December 2017. The Physician Global 
Assessment Scale was used to assess disease severity. Itching/discomfort was evaluated using a visual analogue 
scale. Results: The mean age was 35.8 ± 6.9 years. Severe disease was seen in 53.1%. Complete clearance was 
recorded in 15.6%, 40.6% and 59.4% of patients at weeks two, six and 10, respectively. By week 10, 87.5% had 
achieved marked improvement. Both mean itching and discomfort scores significantly improved at weeks two, six 
and 10 (P <0.001). Better outcomes were significantly associated with disease duration and itching intensity and 
discomfort at presentation (P <0.050). Conclusion: CBD gel should be considered as an option for SSD cases not 
adequately controlled by prior conventional treatment.
Keywords: Seborrheic Dermatitis; Scalp Dermatosis; Betamethasone Dipropionate, Calcipotriol Drug Combination; 
Off-Label Use; Treatment Effectiveness.
امللخ�ص: الهدف: هدفت هذه الدرا�شة اإىل درا�شة ال�شتخدام الغري م�رصح به لهالم مزيج كال�شيبوتريول و بيتاميثازون ديربوبيونات يف 
عالج التهاب اجللد الدهني لفروة الراأ�س املتو�شط اإىل ال�شديد. الطريقة: �شملت هذه الدرا�شة باأثر رجعي 32 مري�شا مع الذين و�شف لهم جل 
يف مركز �شحي �شوباجن جايا، �شيالجنور، �شيالجنور، ماليزيا، بني يناير 2016 ودي�شمرب 2017. مت ا�شتخدام مقيا�س تقييم الطبيب العاملي 
لتقييم �شدة. مت تقييم احلكة/عدم الراحة با�شتخدام مقيا�س التماثلية الب�رصية. النتائج: كان متو�شط العمر 6.9 ± 35.8 �شنة. �شوهد املر�س 
الشديد يف %53.1. من املر�شى. مت ت�شجيل �شفاء كامل يف %15.6، %40.6 و %59.4. من املر�شى يف الأ�شبوع الثاين وال�شاد�س والعا�رص 
على التوايل. بحلول الأ�شبوع العا�رص، حقق %87.5 من املر�شى حت�شنا ملحوظا. و�شجلت قيم احلكة/عدم الراحة حت�شنا ملحوظا يف الأ�شبوع 
 .)P >0.050( وارتبطت النتائج ب�شكل كبري مع مدة املر�س و�شدة احلكة وعدم الراحة وقت عر�س احلالة .)P >0.001( 10 الثاين وال�شاد�س و
اخلال�صة: ينبغي اعتبار هالم مزيج كال�شيبوتريول و بيتاميثازون ديربوبيونات كخيار لعالج حالت التهاب اجللد الدهني لفروة الراأ�س 
التي ي�شعبالتحكم بها عن طريق العالج التقليدي.
ت�رصيح؛ بدون  ا�شتخدام  الدوائي؛  كال�شيبوتريول  مزيج  ديربوبيونات؛  بيتاميثازون  الراأ�س؛  فروة  التهاب  الدهني؛  اجللد  التهاب  املفتاحية:   الكلمات 
فعالية العالج.
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The majority of patients with scalp seborr-hoeic dermatitis improve with antifungal, anti- inflammatory and keratolytic agents which pro- 
vide short-term clearance with minimal side-effects, 
while topical steroids offer better disease control with 
longer remission periods.1–4 However, for those that res- 
pond poorly to conventional treatment, other topical off-
label treatments are sometimes applied. One example 
is a combination of calcipotriol plus betamethasone 
dipropionate (CBD), an effective topical agent for the 
treatment of scalp psoriasis in which complete clearance 
can be seen as early as two weeks.5,6 
Conventional treatments for seborrhoeic dermat- 
itis are based on the presumed pathogenesis and prolif- 
eration of Malassezia furfur and the patient’s heightened 
immunological response.2 Based on the assumption that 
both scalp psoriasis and seborrhoeic dermatitis have 
an inflammatory component in the disease process, the 
use of a CBD gel might be beneficial in treatment of the 
latter condition.7 Moreover, this combination reduces 
the occurrence of side-effects associated with betameth- 
asone dipropionate alone.5 This study therefore aimed 
to investigate the off-label use of a CBD gel in the treat- 
ment of moderate-to-severe scalp seborrhoeic dermatitis.
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Methods
This retrospective study included 32 patients diagnosed 
with scalp seborrhoeic dermatitis at the Subang 
Jaya Medical Centre, Selangor, Malaysia, between 
January 2016 and December 2017. All patients had 
previously undergone conventional SSD treatment 
without adequate response. Cases were diagnosed by 
an attending dermatologist and prescribed twice-weekly 
doses of 50 µg of calcipotriol plus 0.5 mg of betameth- 
asone dipropionate per g of Xamiol® gel (Leo Lab- 
oratories Ltd., Ballerup, Denmark) until resolution. They 
were advised to apply the CBD gel to affected areas and 
to continue using their existing shampoos and taking anti- 
histamines. All of the patients were seen twice weekly 
until the resolution of their scalp lesions and thereafter 
monthly for two months. 
During each patient visit, the attending derma-
tologist recorded the severity of the condition using the 
Physician Global Assessment Scale as either 0 (almost 
clear), 1 (mild), 2 (moderate), 3 (severe) or 4 (very severe) 
based on the degree of erythema and scaling and the 
extent of the skin lesions.8 Patients also self-reported 
symptoms of itchiness and discomfort using a visual 
analogue scale on a scale of 0 (no symptoms) to 10 (most 
severe) during each visit. 
Response to treatment was graded as either com- 
plete clearance, marked improvement (>75% improve-
ment from baseline), moderate improvement (25–75% 
improvement from baseline), mild improvement (<25% 
improvement from baseline) and worsening/no improve- 
ment. A standardised report form was used to document 
all sociodemographic, clinical and treatment data recorded 
during the patient visits. No photographs of the patients’ 
scalps were taken during the course of the study.
Data were analysed using the Statistical Package 
for the Social Sciences (SPSS), Version 13.0 (IBM Corp., 
Armonk, New York, USA). Categorical variables were 
presented as frequencies (percentages), whereas cont- 
inuous variables were presented as means and standard 
deviations. Statistical analysis was performed for cont- 
inuous variables using a Student’s t-test. The level of 
statistical significance was set at P <0.050. This study 
was approved by the local institutional review board 
of Universiti Tunku Abdul Rahman, Kajang, Selangor, 
Malaysia. 
Results
The mean age of the patients was 35.8 ± 6.9 years and 
the majority (53.1%) were female. The mean duration 
of illness was 12.4 ± 8.4 months. Upon initial present-
ation, 15.6% of patients had very severe disease, 53.1% 
had severe disease and 31.3% had moderate disease.
All of the patients had previously demonstrated an 
unsatisfactory response to treatment with antifungals 
with or without tar-based shampoos and topical steroids, 
including desonide, mometasone furoate, betamethasone 
dipropionate, betamethasone dipropionate plus salicylic 
acid and clobetasol propionate lotions. Oral antifungals 
and oral steroids were given to 28.1% and 6.3% of patients, 
respectively. The remaining 65.6% did not receive oral 
treatment. 
By week two of CBD treatment, 53.1% and 15.6% 
demonstrated marked improvement and complete clear- 
ance, respectively. By week six, 40.6% had achieved 
complete clearance; this rate improved to 59.4% by week 
10. By week 10, all patients demonstrated at least 
moderate improvement, with 87.5% achieving either 
complete clearance or marked improvement. One patient 
required oral steroids at week six to control the disease. 
Mean itch scores significantly declined from 6.1 at 
baseline to 2.3, 1.7 and 2.5 at weeks two, six and 10, 
respectively (P <0.001). Similarly, mean discomfort 
scores significantly decreased from 5.6 at baseline to 
1.8, 1.5 and 2.3 at weeks two, six and 10, respectively 
(P <0.001). Patients with marked improvement or 
total clearance had a significantly shorter disease 
duration and decreased itching intensity and discomfort 
at presentation (P <0.050 each) [Table 1]. No adverse 
effects or side-effects were reported. The majority of 
patients (62.5%) discontinued CBD treatment after six 
weeks due to clearance of the lesions and were lost to 
further follow-up.
Table 1: Characteristics of patients with scalp seborrhoeic 
dermatitis after 10 weeks of treatment using a calcipo-
triol plus betamethasone dipropionate gel* (N = 32)
















11.5 ± 7.1 21.0 ± 11.5 0.032
Itching 
score‡
5.9 ± 1.2 8.0 ± 1.2 0.001
Discomfort 
score‡
5.3 ± 1.0 8.3 ± 1.0 <0.001
SD = standard deviation. *Daily Xamiol® gel (Leo Laboratories Ltd., 
Ballerup, Denmark).  †Assessed by an attending dermatologist using the 
Physician Global Assessment Scale as either 0 (almost clear), 1 (mild), 
2 (moderate), 3 (severe) or 4 (very severe).8  ‡Self-reported by patients 
using a visual analogue scale on a scale of 0 (no symptoms) to 10 (most 
severe).
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Discussion
Calcipotriol is a vitamin D analogue licensed for use 
in the treatment of psoriasis; however, it has been used 
extensively as an off-label treatment for a variety of 
other diseases as well.9 Although it has previously been 
studied for the treatment of seborrhoeic dermatitis, it 
did not prove to be effective.10,11 In scalp disease, calci-
potriol was found to result in an inferior clearance rate 
after four weeks compared to a betamethasone valerate 
solution (67.84% versus 90.06%; P <0.05).10 For facial 
seborrhoeic dermatitis, calcipotriol alone resulted in 
a 5% clearance rate at four weeks compared to 40% in 
placebo-treated patients (P <0.05).11
Combining calcipotriol and betamethasone dipro- 
pionate allows for better efficacy and a reduction in the 
side-effects associated with both agents alone.5 In a 
randomised controlled trial, Kragballe et al. observed 
that use of a CBD gel in scalp psoriasis allowed for 
both rapid clearance (due to betamethasone dipropionate) 
and a longer remission period (due to calcipotriol).6 
In the current study, the beneficial effect of the CBD 
gel was noted as early as two weeks, with more than 
half of the patients demonstrating marked improve-
ment. At 10 weeks, 87.5% of patients had marked 
improvement, with significant reductions in itchiness 
and discomfort. This result is comparable to those seen 
in other studies utilising CBD gel for scalp psoriasis 
with rates of complete/near-total clearance ranging from 
68.4–87.5%.5,6,12,13
The present study found that a CBD gel resulted in 
the improvement of scalp lesions among patients who 
did not respond to the prior administration of topical 
steroids. This might have been due to the steroid vehicle 
utilised; most patients had previously used betameth-
asone dipropionate, betamethasone dipropionate plus 
salicylic acid or clobetasol dipropionate lotions containing 
isopropyl alcohol. Local irritation and dryness are common 
adverse effects of such lotions, often contributing to 
non-compliance and discontinuation of treatment.14 
Limitations of this study include its retrospective 
nature, the limited number of patients, the high drop-
out rate following clearance of the scalp lesions, short 
duration of follow-up and the lack of photographs to 
evidence clinical improvement. Ideally, a long-term pros- 
pective randomised case-control study is needed for a 
better comparison of treatment outcomes using CBD gel.
Conclusion
This study found that a CBD gel may be an effective 
option in the treatment of moderate-to-severe seborr-
hoeic dermatitis not adequately controlled by prior conv-
entional treatment with antifungals and steroids. As 
such, it may potentially be recommended in such cases 
as an alternative to conventional treatment, albeit as an 
off-label indication.
conflict of interest
The author declares no conflicts of interest.
funding
No funding was received for this study.
References
1. Kastarinen H, Oksanen T, Okokon EO, Kiviniemi VV, Airola K, 
Jyrkkä J, et al. Topical anti-inflammatory agents for seborrheic 
dermatitis of the face or scalp. Cochrane Database Syst Rev 
2014; CD009446. https://doi.org/10.1002/14651858.CD009446.
pub2.
2. Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of 
seborrheic dermatitis. Am Fam Physician 2015; 91:185−90. 
3. Milani M, Antonio Di Molfetta S, Gramazio R, Fiorella C, 
Frisario C, Fuzio E, et al. Efficacy of betamethasone valerate 0.1% 
thermophobic foam in seborrhoeic dermatitis of the scalp: An 
open-label, multicentre, prospective trial on 180 patients. Curr 
Med Res Opin 2003; 19:342−5. https://doi.org/10.1185/030079 
903125001875.
4. Ortonne JP, Nikkels AF, Reich K, Ponce Olivera RM, Lee JH, 
Kerrouche N, et al. Efficacious and safe management of mod- 
erate to severe scalp seborrhoeic dermatitis using clobetasol 
propionate shampoo 0·05% combined with ketoconazole shampoo 
2%: A randomized, controlled study. Br J Dermatol 2011; 165:171−6. 
https://doi.org/10.1111/j.1365-2133.2011.10269.x.
5. Saraceno R, Camplone G, D’Agostino M, De Simone C, Di Cesare A, 
Filosa G, et al. Efficacy and maintenance strategies of two-
compound formulation calcipotriol and betamethasone dipro-
pionate gel (Xamiol® gel) in the treatment of scalp psoriasis: 
Results from a study in 885 patients. J Dermatolog Treat 2014; 
25:30−3. https://doi.org/10.3109/09546634.2013.800182.
6. Kragballe K, Hoffmann V, Ortonne JP, Tan J, Nordin P, Segaert S. 
Efficacy and safety of calcipotriol plus betamethasone dipro-
pionate scalp formulation compared with calcipotriol scalp sol- 
ution in the treatment of scalp psoriasis: A randomized contr- 
olled trial. Br J Dermatol 2009; 161:159−66. https://doi.org/10.1 
111/j.1365-2133.2009.09116.x.
7. Agozzino M, Berardesca E, Donadio C, Franceschini C, 
de Felice CM, Cavalloti C, et al. Reflectance confocal microscopy 
features of seborrheic dermatitis for plaque psoriasis differ-
entiation. Dermatology 2014; 229:215−21. https://doi.org/10.11 
59/000363289.
8. Pascoe VL, Enamandram M, Corey KC, Cheng CE, Javorsky EJ, 
Sung SM, et al. Using the Physician Global Assessment in a 
clinical setting to measure and track patient outcomes. JAMA 
Dermatol 2015; 151:375−81. https://doi.org/10.1001/jamaderm 
atol.2014.3513.
9. Wat H, Dytoc M. Off-label uses of topical vitamin D in 
dermatology: A systematic review. J Cutan Med Surg 2014; 
18:91−108. https://doi.org/10.2310/7750.2013.13109.
10. Basak PY, Ergin S. Comparative effects of calcipotriol and beta-
methasone 17-valerate solution in the treatment of seborrhoeic 
dermatitis of the scalp. J Eur Acad Dermatol Venereol 2001; 
15:86−8. https://doi.org/10.1046/j.1468-3083.2001.00193-9.x.
11. Berth-Jones J, Adnitt PI. Topical calcipotriol is not effective in 
facial seborrhoeic dermatitis. J Dermatolog Treat 2001; 12:179. 
https://doi.org/10.1080/09546630152608339.
Felix B. Yap
Brief Communication | e523
12. van de Kerkhof PC, Hoffmann V, Anstey A, Barnes L, Bolduc C, 
Reich K, et al. A new scalp formulation of calcipotriol plus beta- 
methasone dipropionate compared with each of its active ingr-
edients in the same vehicle for the treatment of scalp psoriasis: A 
randomized, double-blind, controlled trial. Br J Dermatol 2009; 
160:170−6. https://doi.org/10.1111/j.1365-2133.2008.08927.x.
13. Ma L, Yang Q, Yang H, Wang G, Zheng M, Hao F, et al. Calcip- 
otriol plus betamethasone dipropionate gel compared with calci- 
potriol scalp solution in the treatment of scalp psoriasis: A rand- 
omized, controlled trial investigating efficacy and safety in a 
Chinese population. Int J Dermatol 2016; 55:106−13. https://
doi.org/10.1111/ijd.12788.
14. Katz HI, Lindholm JS, Weiss JS, Shavin JS, Morman M, 
Bressinck R, et al. Efficacy and safety of twice-daily augmented 
betamethasone dipropionate lotion versus clobetasol propionate 
solution in patients with moderate-to-severe scalp psoriasis. Clin 
Ther 1995; 17:390−401. https://doi.org/10.1016/0149-2918(95)8 
0104-9.
